Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Clin Chem Lab Med ; 56(2): 312-322, 2018 01 26.
Article in English | MEDLINE | ID: mdl-28771430

ABSTRACT

BACKGROUND: Serum free light chain (sFLC) measurements are increasingly important in the context of screening for monoclonal gammopathies, prognostic stratification, and monitoring of therapy responses. At the same time, analytical limitations have been reported with the currently available nephelometric and turbidimetric sFLC assays. We have evaluated a new quantitative sFLC ELISA for its suitability in routine clinical use. METHODS: Reference ranges of the Sebia FLC assay were calculated from 208 controls. Assay interference, reproducibility, lot-to-lot variability, and linearity were assessed. Method comparison to the Freelite assay (Binding Site) was conducted by retrospective analysis of 501 patient sera. RESULTS: Reference ranges of the Sebia κ/λFLC-ratio were 0.37-1.44. We observed good sensitivity (1.5 mg/L) and linearity in both polyclonal and monoclonal sFLC samples and never experienced antigen excess. Sebia FLC reproducibility varied between 6.7% and 8.1% with good lot-to-lot consistency. Method comparison with Freelite showed the following correlations: κFLC R=0.94, λFLC R=0.92 and κ/λFLC-ratio R=0.96. The clinical concordance of the κ/λFLC-ratio of both methods was 94%. Significant quantitative differences were observed between both methods, mainly in sera with high FLC concentrations. The Sebia monoclonal FLC concentrations were coherent with those obtained by serum protein electrophoresis (SPE). Freelite monoclonal FLC concentrations were consistently higher, with a mean 12-fold overestimation compared to SPE. CONCLUSIONS: The Sebia FLC assay provides a novel platform for sensitive and accurate sFLC measurements. The Sebia FLC showed good clinical concordance with Freelite. Further studies are warranted to confirm the clinical value of this assay.


Subject(s)
Enzyme-Linked Immunosorbent Assay/methods , Immunoglobulin kappa-Chains/blood , Immunoglobulin lambda-Chains/blood , Blood Protein Electrophoresis/methods , Data Accuracy , Humans , Nephelometry and Turbidimetry , Reproducibility of Results
2.
Sci Rep ; 7: 43486, 2017 03 07.
Article in English | MEDLINE | ID: mdl-28344338

ABSTRACT

Keyhole limpet hemocyanin (KLH) is used as an immunogenic neo-antigen for various clinical applications and during vaccine development. For advanced monitoring of KLH-based interventions, we developed a flow cytometry-based assay for the ex vivo detection, phenotyping and isolation of KLH-specific B cells. As proof-of-principle, we analyzed 10 melanoma patients exposed to KLH during anti-cancer dendritic cell vaccination. Our assay demonstrated sensitive and specific detection of KLH-specific B cells in peripheral blood and KLH-specific B cell frequencies strongly correlated with anti-KLH serum antibody titers. Profiling of B cell subsets over the vaccination course revealed that KLH-specific B cells matured from naïve to class-switched memory B cells, confirming the prototypic B cell response to a neo-antigen. We conclude that flow-cytometric detection and in-depth phenotyping of KLH-specific B cells is specific, sensitive, and scalable. Our findings provide novel opportunities to monitor KLH-specific immune responses and serve as a blueprint for the development of new flow-cytometric protocols.


Subject(s)
Adjuvants, Immunologic/chemistry , B-Lymphocyte Subsets/immunology , Cancer Vaccines/therapeutic use , Dendritic Cells/transplantation , Hemocyanins/chemistry , Melanoma/therapy , Skin Neoplasms/therapy , Antibodies/blood , B-Lymphocyte Subsets/classification , B-Lymphocyte Subsets/pathology , Cell Tracking/methods , Dendritic Cells/chemistry , Dendritic Cells/cytology , Dendritic Cells/immunology , Enzyme-Linked Immunospot Assay , Flow Cytometry , Humans , Immunologic Memory , Immunophenotyping , Melanoma/immunology , Melanoma/pathology , Skin Neoplasms/immunology , Skin Neoplasms/pathology , Vaccination/methods
3.
Cancer Immunol Immunother ; 61(11): 2003-11, 2012 Nov.
Article in English | MEDLINE | ID: mdl-22527252

ABSTRACT

PURPOSE: Keyhole limpet hemocyanin (KLH) attracts biomedical interest because of its remarkable immunostimulatory properties. Currently, KLH is used as vaccine adjuvant, carrier protein for haptens and as local treatment for bladder cancer. Since a quantitative human anti-KLH assay is lacking, it has not been possible to monitor the dynamics of KLH-specific antibody (Ab) responses after in vivo KLH exposure. We designed a quantitative assay to measure KLH-specific Abs in humans and retrospectively studied the relation between vaccination parameters and the vaccine-induced anti-KLH Ab responses. EXPERIMENTAL DESIGN: Anti-KLH Abs were purified from pooled serum of melanoma patients who have responded to KLH as a vaccine adjuvant. Standard isotype-specific calibration curves were generated to measure KLH-specific Ab responses in individual serum samples using ELISA. RESULTS: KLH-specific IgM, IgA, IgG and all IgG-subclasses were accurately measured at concentrations as low as 20 µg/ml. The intra- and inter-assay coefficients of variation of this ELISA were below 6.7 and 9.9 %, respectively. Analyses of 128 patients demonstrated that mature DC induced higher levels of KLH-specific IgG compared to immature DC, prior infusion with anti-CD25 abolished IgG and IgM production and patients with locoregional disease developed more robust IgG responses than advanced metastatic melanoma patients. CONCLUSIONS: We present the first quantitative assay to measure KLH-specific Abs in human serum, which now enables monitoring both the dynamics and absolute concentrations of humoral immune responses in individuals exposed to KLH. This assay may provide a valuable biomarker for the immunogenicity and clinical effectiveness of KLH-containing vaccines and therapies.


Subject(s)
Antibodies/blood , Cancer Vaccines/immunology , Dendritic Cells/immunology , Enzyme-Linked Immunosorbent Assay , Hemocyanins/immunology , Melanoma/therapy , Adjuvants, Immunologic/therapeutic use , Cancer Vaccines/therapeutic use , Female , Humans , Immunity, Humoral , Immunotherapy , Male , Melanoma/immunology , Reproducibility of Results , Retrospective Studies
SELECTION OF CITATIONS
SEARCH DETAIL
...